Trial Profile

A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of RT-111- RaniPill Capsule Containing Ustekinumab - Administered Orally to Healthy Volunteers

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 13 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ustekinumab (Primary) ; Ustekinumab
Indications Crohn's disease; Psoriasis; Psoriatic arthritis; Ulcerative colitis
Focus Pharmacokinetics
Sponsors Rani Therapeutics

09 May 2024 According to a Rani Therapeutics media release, data on the RaniPill capsule to be presented, at Digestive Disease Week (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC.
05 Feb 2024 Primary endpoint has been met. (Evaluate AUC of ustekinumab administered via the RaniPill capsule), according to a Rani Therapeutics media release.
05 Feb 2024 Primary endpoint has been met. (Evaluate Tmax of ustekinumab administered via the RaniPill capsule), according to a Rani Therapeutics media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com